百令胶囊治疗早期糖尿病肾病的系统评价

目的系统评价百令胶囊治疗早期糖尿病肾病（DN）的有效性和安全性。方法采用Cochrane系统评价方法，计算机检索MED-LINE，VIP，CNKI，万方数据库和PubMed数据库。按纳入和排除标准由2名评价者独立选择试验、提取资料、交叉核对并进行方法学质量评估，采用RevMan5．0软件进行Meta分析。结果共纳入16个研究，包括1035例患者。Meta分析结果显示，尿微量白蛋白排泄率（UAER）WMD=-25．49，95％CI（-33．42，-18．47），P〈0．00001]．24h尿蛋白定量WMD=-0．07，95％c，（-0．12，-0．03），P=0．001]、C反应蛋白（CRP）WMD=-1．29，95％CI（-1．72，-0．86），P〈0．00001]，白令胶囊治疗组均优于常规治疗组；仅有7个研究提及百令胶囊治疗期间有无不良反应或毒副作用，均未见严重不良反应事件。结论系统评价结果初步显示，百令胶囊可以降低早期糖尿病肾病患者的UAER、24h尿蛋白定量、CRP相对安全,值得临床推广。

Systematic Evaluation on Bailing Capsule for Treating Early Diabetic Nephropathy

Objective To systematically evaluate the efficacy and safety of Bailing Capsule for treating early diabetic nephropathy（DN）. Methods The systematic evaluation method was adopted to retrieve the Medline,VIP,CNKI,Wanfang Database and PubMed by com- puter. Two valuators independently selected the trials,collected the data,conducted the cross- check,performed the methodological quality evaluation and Meta analysis by RevMan 5.0 software. Results 16 randomized controlled trials met the inclusion criteria, involving 1 035 patients. The Meta- analysis based on the included trials showed that the Bailing Capsule group was better than the routine treatment group in UAERWMD = - 25.49,95% CI（ - 33.42, - 18.47）, P 〈 0. 000 01 ], 24 h urinary proteinWMD -： - 0.07,95% CI （-0.12,-0.03）,P=0.001] and CRP WMD=-1.29,95% CI（-1.72,-0.86）,P 〈 0.00001];Only 7 trials mentioned the ad- verse reactions during treatment, no serious adverse events were seen. Conclusion The systematic evaluation preliminarily shows that Bailing Capsule can reduce UAER, 24 h urinary protein and CRP with relative safety in treating the patients with early DN, which is worthy of being clinically popularized.